Latest News
Dr. David Bar-Or retires as Chief Scientific Officer of Ampio Pharmaceuticals
Date: September 4, 2018 | READ MORE >
Ampio Reports New Publication on the Mechanisms of Action for Ampion™
Date: June 27, 2018 | READ MORE >
Ampio Provides Scientific Update and Links to Peer Review Publications
Date: June 5, 2018 | READ MORE >
Ampio Pharmaceuticals Provides Corporate Update Following Conference Call
Date: March 16, 2018 | READ MORE >
Ampio Update of J.P. Morgan Meeting Events and Disease Modification Discussions
Date: January 16, 2018 | READ MORE >
Ampio Pharmaceuticals, Inc. Announces Continued Listing Plan Accepted by NYSE American
Date: November 16, 2017 | READ MORE >
Ampio Pharmaceuticals, Inc. Announces Closing of Registered Direct Offering
Date: October 18, 2017 | READ MORE >
Ampio Pharmaceuticals, Inc. Announces Pricing of Registered Direct Offering
Date: October 16, 2017 | READ MORE >
Ampio Completes Enrollment of Patients in 12-Week Pivotal Trial
Date: September 18, 2017 | READ MORE >
Ampio Pharmaceuticals, Inc. Announces Annual Shareholder Meeting
Date: September 8, 2017 | READ MORE >
Ampio Injects First Patient in Final Pivotal Clinical Trial for Ampion™ BLA
Date: June 22, 2017 | READ MORE >
Ampio Pharmaceuticals, Inc. Announces Pricing of Registered Direct Offering
Date: August 29, 2016 | READ MORE >
Ampio Announces 2016 Corporate Update on Thursday, January 28, 4:30pm EST
Date: January 25, 2016 | READ MORE >
Ampio’s OptimEyes Study Results to be presented at World Ophthalmology Congress
Date: January 11, 2016 | READ MORE >
Ampio Intends to Distribute Aytu BioScience Stock to Ampio Shareholders
Date: November 2, 2015 | READ MORE >
Ampio Updates Status of Clinical Trials and Manufacturing Facility
Date: November 12, 2014 | READ MORE >